Research Article
Lack of Association between Poor Glycemic Control in T2DM and Subclinical Hypothyroidism

Pragya Sharma,1 Rashmi Sinha,1 Anupa Prasad2, and J. K. Mitra1
1Department of Medicine, Rajendra Institute of Medical Sciences (RIMS), Ranchi, India
2Biochemistry Department, Rajendra Institute of Medical Sciences (RIMS), Ranchi, India

Correspondence should be addressed to Anupa Prasad; anupaprasad651@gmail.com

Received 20 June 2020; Revised 16 July 2020; Accepted 29 August 2020; Published 8 September 2020

1.Introduction

Type 2 diabetes mellitus (T2DM) and hypothyroidism are the two most common endocrinological disorders. Both diseases are multifactorial in origin and have been implicated in the causation of dyslipidemia, dermatological diseases, atherosclerosis, and myocardial dysfunction, as well as endothelial dysfunction [1–3]. Type 2 diabetes mellitus (T2DM) has been associated with subclinical hypothyroidism (SCH) [4, 5]. The prevalence of SCH is more in patients with T2DM (2.2% to 17%) than the general population (4 to 10%) [6–9]. However, in some of the studies, no such difference has been observed between the two of them [8]. More studies are needed to confirm the association of T2DM with SCH. Little is known about the association of SCH with glycemic control in Indian T2DM patients. Given the aforementioned facts, we attempted to find out the prevalence of subclinical hypothyroidism (SCH) in type 2 diabetes mellitus (T2DM) and its association with glycemic control.

1.1. Subjects.

205 consecutive patients of T2DM visiting the outpatient department of medicine were included in the study. The diagnosis of T2DM was based on the American Diabetes Association (ADA) 2018 criteria for the diagnosis of DM [10].

Inclusion criteria: the patients diagnosed with type 2 DM with age >40 years were included in the group.

Exclusion criteria: the exclusion criteria were unwillingness to participate in the study, known history of thyroid disease, surgery of the thyroid gland, radiation exposure to the thyroid gland, pregnancy, patients on medications known to modify the thyroid functions such as glucocorticoids, lithium, and amiodarone, unstable cardiac disease, renal impairment, liver cirrhosis, malignancies, and other
types of DM such as secondary DM, gestational DM, or type 1 DM.

2. Materials and Methods

2.1. Sample Size. The sample size was based on our previous study in which the prevalence of subclinical hypothyroidism was 13.7% [11]. Considering a confidence level of 95% and an acceptable margin of error as 5%, the required sample size was calculated to be 182. Expecting an attrition rate of 20%, a total of 218 patients were selected for the study. Out of 218, 3 patients were excluded as they were not willing to participate in the study. Another two patients were found to be overt hypothyroid, while eight other patients had comorbid conditions, and so, they were also excluded. Finally, 205 patients were recruited for the study.

2.2. Baseline Data. For each of the study participants, data regarding age, sex, weight, and medical and family history were collected and recorded in a pro forma. The weight of the participants was measured using an analog scale with an accuracy of 0.5 kg.

2.3. Biochemical Assessment. The liver function test, kidney function test, fasting lipid profile, and fasting glucose levels were estimated by the photometric method using BA 400 from BioSystems Diagnostics Private Ltd. The HbA1c levels were assessed on the D10 HPLC system from Bio-Rad Clinical Diagnostics. Serum TSH, free T3, and free T4 were estimated using the enhanced chemiluminescence method on i1000 SR from Abbott. SCH was defined as an elevated estimated using the enhanced chemiluminescence method on i1000 SR from Abbott. SCH was defined as an elevated

2.4. Statistical Analysis. Data analysis was conducted with SPSS version 20.0 (SPSS Inc., Chicago, IL, USA). The association between categorical variables was examined with the chi-square test. Differences in continuous variables between the 2 independent study groups were analyzed with the independent sample t-test. Pearson correlation coefficients were calculated to test for associations between TSH and age and duration of diabetes, as well as glycosylated hemoglobin (HbA1c). Linear regression analysis was used to determine whether the relation between HbA1c and TSH remained significant after adjusting for age, duration of diabetes, and lipid profile. Significance was set at $p < 0.05$, and all tests were 2-tailed.

3. Results

The mean age of T2DM patients in the euthyroid and the hypothyroid group was similar (55.25 vs. 55.23 years). The mean duration of T2DM was 7.3 years in the euthyroid group, whereas it was 6.1 years in the SCH group. The baseline characteristics of the euthyroid and subclinical hypothyroid type 2 DM patients are presented in Table 1. Females constituted 53.66% of the type 2 diabetic population. The male-to-female ratio was 1:1.16. The prevalence of SCH was higher in women compared to men. Figure 1 shows the prevalence of SCH in men and women.

The prevalence of SCH in the HbA1c < 7% category was 27%, whereas it was 33% in the category with HbA1c > 9%. Hence, SCH was more prevalent in the poor glycemic control group. Figure 2 shows the prevalence of subclinical hypothyroidism in different categories of HbA1c.

One-way analysis of variance was conducted to evaluate the null hypothesis that there is no difference in glycemic control with the rise in TSH. The independent variable, HbA1c, was categorized into three groups: <7% (better glycemic control), 7–9%, and >9% (poor glycemic control). The assumption of normality was evaluated using histograms and found tenable for all the groups. The assumption of homogeneity of variance was tested, and it was untenable. We then looked into the robust test of equality of means, and it was significant $(p = 0.01)$. We, therefore, concluded that there is a significant difference in glycemic control with the TSH level.

In the independent sample t-test, TSH in the group with HbA1c < 7% was $3.36 \pm 2.38 \mu U/ml$, which was lower than the TSH in the HbA1c >9% group where it was $4.43 \pm 2.36 \mu U/ml$. This difference was statistically significant $(p = 0.026)$.

We tried to find out the association between HbA1c categories and the TSH. The linear regression model showed a weak significant correlation between the two of them $(r = 0.156; p = 0.026)$.

We then investigated the relationship between subclinical hypothyroidism and glycemic control in T2DM patients using multinomial logistic regression analysis. When a full model containing all the predictors was compared against a null model, the full model represented a significant improvement in fit over the null model. The likelihood ratio test for the contribution of SCH for poor glycemic control revealed that SCH was not a significant predictor in the model ($X^2 = 1.046; p = 0.593$). We failed to reject the null hypothesis and concluded that, for the HbA1c > 9% category relative to the HbA1c < 7% category, the regression coefficient for SCH is not statistically different from zero given age, duration of diabetes, serum total cholesterol, HDL-cholesterol, and serum triglycerides in the model. Table 2 shows the multivariate logistic regression analysis of the association between subclinical hypothyroidism and glycemic control in patients with type 2 diabetes mellitus.

4. Discussion

The present study showed that, in Indian diabetic patients, the prevalence of SCH was 23.4%. This was consistent with the findings of Ghosh et al., who reported a 23% prevalence of SCH in T2DM patients in Eastern India [12]. Our finding was higher than the study by Akbar et al., who reported that thyroid dysfunction was present in 16% of Saudi T2DM patients [13] and Perros et al., who reported an estimated prevalence of 13.4% of thyroid dysfunction in T2DM patients [6]. Celani et al. investigated the prevalence of SCH in type 2 DM, and it was found to be 48.3% [14]. Such a high incidence of SCH could be attributed to the advanced age
Table 1: Baseline characteristics of the euthyroid and subclinical hypothyroid type 2 DM patients.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Euthyroid (n = 157)</th>
<th>Subclinical hypothyroid (n = 48)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Men (n = 80)</td>
<td>Women (n = 77)</td>
</tr>
<tr>
<td>Age in years (mean ± SD)</td>
<td>55.73 ± 10.52</td>
<td>54.77 ± 10.68</td>
</tr>
<tr>
<td>Duration of diabetes in years (mean ± SD)</td>
<td>7.61 ± 5.98</td>
<td>6.97 ± 4.61</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>7.63 ± 1.13</td>
<td>8.15 ± 1.78</td>
</tr>
<tr>
<td>Free T3 (pg/ml) (mean ± SD)</td>
<td>2.75 ± 0.72</td>
<td>2.96 ± 0.61</td>
</tr>
<tr>
<td>Free T4 (µg/dl) (mean ± SD)</td>
<td>2.54 ± 1.11</td>
<td>2.62 ± 1.24</td>
</tr>
<tr>
<td>Total cholesterol (mg/dl) (mean ± SD)</td>
<td>183 ± 40</td>
<td>182 ± 36</td>
</tr>
<tr>
<td>HDL cholesterol (mg/dl) (mean ± SD)</td>
<td>42.27 ± 7.88</td>
<td>42.16 ± 6.39</td>
</tr>
<tr>
<td>Triglycerides (mg/dl) (mean ± SD)</td>
<td>152.75 ± 48.70</td>
<td>150.61 ± 41.98</td>
</tr>
<tr>
<td>LDL cholesterol (mg/dl) (mean ± SD)</td>
<td>105.61 ± 32.11</td>
<td>113.17 ± 35.50</td>
</tr>
</tbody>
</table>

*p values for comparison of the mean values between the subclinical hypothyroid and euthyroid subjects by independent sample t-test, p value <0.05.

Figure 1: Prevalence of SCH in men and women.

Figure 2: Prevalence of subclinical hypothyroidism in the three categories of HbA1c.

Table 2: Multivariate logistic regression analysis of the association between subclinical hypothyroidism and glycemic control in patients with type 2 diabetes mellitus.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Beta</th>
<th>OR (95% CI)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>All ages</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HbA1c &lt; 7%</td>
<td>Reference</td>
<td>Reference</td>
<td>Reference</td>
</tr>
<tr>
<td>HbA1c 7–9%</td>
<td>−0.693</td>
<td>0.500 (0.117–2.135)</td>
<td>0.350</td>
</tr>
<tr>
<td>HbA1c &gt; 9%</td>
<td>−0.154</td>
<td>0.857 (0.14–5.20)</td>
<td>0.867</td>
</tr>
</tbody>
</table>

Adjusted for age, duration of diabetes, total cholesterol, high-density lipoprotein cholesterol, and triglyceride. OR: odds ratio; CI: confidence interval. p < 0.05 is significant.

The mean duration of T2DM was 7.3 years in the euthyroid group, whereas it was 6.1 years in the SCH group. This was contrary to the observation by Ezeani et al. who found that the mean duration of diabetes in the SCH group was higher (9.5 years) than that in the euthyroid group (6.0 years) [16]. Our observation could be attributed to more symptomatic patients leading to the early diagnosis in the SCH group. No significant relationships were found between the presence of SCH and age or duration of T2DM.

Mean HbA1c in the euthyroid group was 7.89%, whereas it was higher (8.33%) in the SCH group, but the difference was statistically not significant (p = 0.09). Mean HbA1c of 8.33% observed in T2DM patients in this study is similar to 8.3% reported by the Diabcare Nigeria study group [17].
TSH in the group with HbA1c < 7% was 3.36 μIU/mL, which was lower than the TSH in the HbA1c > 9% group where it was 4.43 μIU/mL. This difference was statistically significant (p = 0.026). The linear regression model showed a weak significant correlation between the HbA1c categories and the TSH (r = 0.156; p = 0.026). However, in multivariate logistic regression analysis, after adjustment of age and duration of diabetes, for the HbA1c > 9% category when compared with the HbA1c < 7% category, high TSH was not a significant predictor. This finding was consistent with the results of Khalid et al., who did not find any association between T2DM and hypothyroidism [18]. Our finding was in contrast to the findings of Ezeani et al. [16], Cho et al. [19], and Makadia et al. [20], who found a strong association of HbA1c with thyroid dysfunction. We demonstrated no association between SCH and poor glycemic control in patients with T2DM.

The strength of our study was the matching age group of the study participants in both euthyroid and subclinical hypothyroid categories.

The limitations of the study were that the authors did not evaluate anti-TPO antibodies.

5. Conclusion
A high prevalence of SCH in T2DM patients suggests that there is a need for regular follow-up to check the progression of SCH to overt hypothyroidism. High serum TSH is not a predictor of poor glycemic control.

Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
The authors declare no conflicts of interest related to this manuscript.

Authors’ Contributions
Dr. Pragya Sharma conceived the study, designed the concept, and collected the data. Dr. Anupa Prasad and Dr. Rashmi Sinha prepared the manuscript, analyzed the data, and performed the statistical analysis. Dr. J. K. Mitra critically reviewed the article.

Acknowledgments
The authors are thankful to the Department of Lab Medicine and the Department of Biochemistry for extending their help in work.

References